Thiamine: Difference between revisions
3amrbadawy (talk | contribs) No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
| (17 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Dosage Forms: 50,100,250,500mg | |||
*Dosage Forms: | *Routes of Administration: IM, IV | ||
*Routes of Administration: | **Im or IV routres require: Intradermal skin test before use if hypersensitivity risk | ||
*Common Trade Names: | *Common Trade Names: Vitamin B1 | ||
==Adult Dosing== | ==Adult Dosing== | ||
*[[Beriberi]] | |||
**10-20mg IM tid x 2wk | |||
***Then 5-30mg PO QD x1mo | |||
*Wet beriberi with CHF | |||
**10-30mg IV tid | |||
*[[Wernicke-Korsakoff syndrome|Wernicke's encephalopathy]] | |||
**High-dose parenteral regimen: 500mg IV TID x 2 days | |||
***Then 250mg IM/IV QD x 5 days | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: A (according to dietary reference intake) | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Safe | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
Not defined | |||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
Not defined | |||
==Contraindications== | ==Contraindications== | ||
| Line 24: | Line 33: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*anaphylaxis | |||
*angioedema | |||
*cyanosis | |||
===Common=== | ===Common=== | ||
*injection site pain | |||
*pruritus | |||
*warmth sensation | |||
*urticaria | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: Unknown | ||
*Metabolism: | *Metabolism: Liver, CYP450, Unknown | ||
*Excretion: | *Excretion: Urine | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Physiologic cofactor | |||
==Comments== | ==Comments== | ||
| Line 40: | Line 57: | ||
==References== | ==References== | ||
*[https://online.epocrates.com/drugs/188810/vitamin-B1-common-name/Monograph Epocrates: Vitamin B1] | |||
<references/> | <references/> | ||
[[Category: | [[Category:Pharmacology]] | ||
[[Category:FEN]] | |||
Latest revision as of 00:07, 22 October 2020
Administration
- Dosage Forms: 50,100,250,500mg
- Routes of Administration: IM, IV
- Im or IV routres require: Intradermal skin test before use if hypersensitivity risk
- Common Trade Names: Vitamin B1
Adult Dosing
- Beriberi
- 10-20mg IM tid x 2wk
- Then 5-30mg PO QD x1mo
- 10-20mg IM tid x 2wk
- Wet beriberi with CHF
- 10-30mg IV tid
- Wernicke's encephalopathy
- High-dose parenteral regimen: 500mg IV TID x 2 days
- Then 250mg IM/IV QD x 5 days
- High-dose parenteral regimen: 500mg IV TID x 2 days
Pediatric Dosing
Special Populations
- Pregnancy Rating: A (according to dietary reference intake)
- Lactation risk: Safe
Renal Dosing
Not defined
Hepatic Dosing
Not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- anaphylaxis
- angioedema
- cyanosis
Common
- injection site pain
- pruritus
- warmth sensation
- urticaria
Pharmacology
- Half-life: Unknown
- Metabolism: Liver, CYP450, Unknown
- Excretion: Urine
Mechanism of Action
Physiologic cofactor